Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 166

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 166
---
 be able to derive
from the sale of any products.

There can be no assurance
that any of our product candidates will be accepted by the marketplace as readily as these or other competing treatments. Furthermore,
if our competitors’ products are approved before ours, it could be more difficult for us to obtain approval from the FDA. Even if
our products are successfully developed and approved for use by all governing regulatory bodies, there can be no assurance that physicians
and patients will accept our product(s) as a treatment of choice.

Furthermore, the pharmaceutical
research industry is diverse, complex, and rapidly changing. By its nature, the business risks associated therewith are numerous and significant.
The effects of competition, intellectual property disputes, market acceptance, and FDA regulations preclude us from forecasting revenues
or income with certainty or even confidence.

We
have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently
profitable, and we may never achieve or sustain profitability. 

We were formed in September
2015 and have only a limited operating history and have incurred losses since our formation. We continue to incur significant development
and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses
in each period since our inception, resulting in substantial doubt in our ability to continue as a going concern. We reported a net loss
of $42.1 million and $30.0 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, we
had cash and cash equivalents of $20.9 million and $35.8 million, respectively.

We expect to continue to incur significant losses for the foreseeable
future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our
product candidates and now that we are no longer an emerging growth company, as defined in Section 2(a) of the Securities Act of 1933,
as amended. As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the Dodd-Frank
Act, as well as rules adopted, and to be adopted, by the SEC and The Nasdaq Stock Market LLC. We also expect that compliance with the
auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and increased disclosure requirements